Books > Medicine > Surgery > Transplant surgery
|
Buy Now
Blood and Marrow Transplantation Long Term Management - Prevention and Complications Second Edition (Hardcover, 2nd Edition)
Loot Price: R4,011
Discovery Miles 40 110
|
|
Blood and Marrow Transplantation Long Term Management - Prevention and Complications Second Edition (Hardcover, 2nd Edition)
Expected to ship within 12 - 17 working days
|
Blood and Marrow Transplantation Long Term Management Hematopoietic
cell transplantation (HCT) provides curative therapy for a variety
of diseases. Over the past several decades, significant advances
have been made in the field of HCT, to the point where HCT has
become an integral part of treatment modality for a variety of
hematologic malignancies and some nonmalignant diseases. HCT
remains an important treatment option for a wide variety of
hematologic and nonhematologic disorders, despite recent advances
in the field of immunologic therapies. Factors driving this growth
include expanded disease indications, greater donor options
(expanding unrelated donor registries and haploidentical HCT), and
accommodation of older and less fit recipients. The development of
less toxic pretransplant conditioning regimens, more effective
prophylaxis of graft-versus-host disease (GVHD), improved infection
control, and other advances in transplant technology have resulted
in a rapidly growing number of transplant recipients surviving
long-term free of the disease for which they were transplanted. The
changes over decades in the transplant recipient population and in
the practice of HCT will have almost inevitably altered the
composition of the long-term survivor population over time. Apart
from an increasingly older transplant recipient cohort, the pattern
of transplant indications has shifted from the 1990s when chronic
myeloid leukemia made up a significant proportion of allo-HCT
indications. Changes in cell source, donor types, conditioning
regimens, GVHD prophylaxis, and supportive care have all occurred,
with ongoing reductions in both relapse and non-relapse mortality
(NRM) have been demonstrated. These patients have increased risks
for a variety of late complications, which can cause morbidity and
mortality. Most long-term survivors return to the care of their
local hematologists/oncologists or primary care physicians, who may
not be familiar with specialized monitoring and management of long
complications after HCT for this patient population. As HCT
survivorship increases, the focus of care has shifted to the
identification and treatment of long-term complications that may
affect quality of life and long-term morbidity and mortality.
Preventive care as well as early detection and treatments are
important aspects to reducing morbidity and mortality in long-term
survivors after allo-HCT. This second edition, Blood and Marrow
Transplantation Long Term Management: Survivorship after
Transplant, provides up-to-date information about diagnosis,
screening, treatment, and long-term surveillance of long-term
survivors after HCT.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.